Key Takeaways & Executive Findings
- •• The gut microbiota and intestinal motility form a bidirectional homeostatic system, with dysbiosis and impaired motility creating a self-reinforcing vicious cycle. • Four regulatory axes (metabolic, neuronal, immunological, mechanical) mediate microbiota-driven motility, with key pathways including butyrate-5-HT, tryptophan-AhR, and microbiota-ammonia-ACh. • Four self-reinforcing pathological sub-loops (butyrate-hypoxia, Piezo2-Fusobacterium, ENS damage, brain-gut axis) drive disease progression and explain resistance to spontaneous recovery. • Multi-node combination interventions targeting pathogen clearance, butyrate restoration, metabolic compensation, and circadian alignment offer promising therapeutic strategies.
Abstract
Intestinal motility is essential for nutrient absorption, waste excretion, and toxin clearance, and its impairment underlies functional constipation, slow-transit constipation, and irritable bowel syndrome. While traditional research has focused on smooth muscle contractility and enteric nervous system (ENS) autonomy, emerging evidence highlights the gut microbiota as a critical regulator. This perspective article synthesizes recent findings into the 'Microbiota-Mediated Regulation and Intervention of Intestinal Motility' model, proposing that dysmotility arises from a vicious cycle of microbiota dysbiosis, impaired motility, and exacerbated dysbiosis. The model integrates four regulatory axes—metabolic, neuronal, immunological, and mechanical—through which the microbiota positively drives motility. Key pathways include the butyrate-5-HT axis, tryptophan-aryl hydrocarbon receptor signaling, microbiota-immune balance, and a novel microbiota-ammonia-acetylcholine metabolic compensation pathway. Under pathological conditions, four self-reinforcing sub-loops (butyrate-hypoxia, Piezo2-Fusobacterium, ENS damage, and brain-gut axis) perpetuate the cycle. The model's novelty lies in explicitly integrating these loops and proposing multi-node combination intervention strategies, including pathogen clearance with probiotic augmentation, combined butyrate and prokinetic therapy, metabolic compensation with neuroprotection, and chronoregulatory approaches. This framework provides a comprehensive basis for understanding and treating intestinal motility disorders.
1. Introduction
Intestinal motility underpins nutrient absorption, waste excretion, and toxin clearance. Its impairment is a core pathological feature of functional constipation, slow-transit constipation, irritable bowel syndrome, and related disorders. Traditional research has emphasized the intrinsic contractile properties of intestinal smooth muscle and the autonomous rhythmicity of the enteric nervous system (ENS). However, mounting evidence indicates that the gut microbiota and its metabolites are indispensable regulators of intestinal motility [1]. The data indicate that microbiota and intestinal motility form a bidirectional, homeostatic regulatory system: hypothalamic neurons can rapidly remodel the gut microbiota [2]; the microbiota participates in motility regulation via mechanosensitive channels such as Piezo2 [3]; and transit time critically shapes microbial composition and metabolism [4].
In this perspective article, we synthesize recent findings into a model—termed the 'Microbiota-Mediated Regulation and Intervention of Intestinal Motility' model. We propose that the core pathological pattern of dysmotility is a vicious cycle of 'microbiota dysbiosis→impaired intestinal motility→exacerbated dysbiosis'. Specifically, gut microbiota positively drives intestinal motility through a four-axis network of metabolic, neuronal, immunological, and mechanical signaling; impaired motility, in turn, exacerbates microbiota imbalance by prolonging transit time, altering mechanical signals, and disrupting the anaerobic microenvironment; microbiota-based interventions can restore metabolic capacity and signaling pathways, break the vicious cycle, and reestablish intestinal motility homeostasis. The novelty of this model lies in explicitly integrating four self-reinforcing pathological sub-loops and proposing multi-node combination strategies, as well as articulating a threshold-based transition from compensation to decompensation.
Loading authentic research manuscript (Pages 1–5)...
WU Zhengwen (2026). A Model for Microbiota-Mediated Regulation and Intervention of Intestinal Motility. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2026128
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the core pathological cycle in intestinal motility disorders?
The core pathological cycle is a self-reinforcing vicious cycle: microbiota dysbiosis leads to impaired intestinal motility, which in turn exacerbates dysbiosis by prolonging transit time, altering mechanical signals, and disrupting the anaerobic microenvironment.
How does butyrate influence intestinal motility?
Butyrate, a short-chain fatty acid, promotes serotonin (5-HT) synthesis in enterochromaffin cells via activation of FFAR2/FFAR3/GPR109A and inhibition of histone deacetylases, thereby enhancing ENS excitability and smooth muscle contractility.
What are the four self-reinforcing pathological sub-loops?
The four sub-loops are: (1) butyrate-hypoxia loop, (2) impaired motility and Piezo2-Fusobacterium loop, (3) ENS damage loop, and (4) brain-gut axis central loop. These loops overlap to drive disease progression.
What multi-node intervention strategies are proposed?
Strategies include: (1) pathogen clearance with functional probiotic augmentation, (2) combined restoration of butyrate production and motility, (3) metabolic compensation with neuroprotection, and (4) chronoregulatory approaches to synchronize host-microbiota rhythms.
What is the microbiota-ammonia-ACh pathway?
This pathway involves gut microbiota upregulating urease activity to increase ammonia production, which promotes acetylcholine (ACh) release by upregulating Cav2.1, thereby enhancing neuromuscular transmission and intestinal motility. It requires independent replication.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.